GlassScriptPhysician profile
Tyrel K Somers
NPI 1174879936
$2,429.02
in general payments reported to CMS, 2019-2025
30 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $35.61 · 2021: $401 · 2022: $346 · 2023: $357 · 2024: $489 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $312.07 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $291.06 | 2021-2025 | Qulipta, Vraylar, Teflaro |
| Sunovion Pharmaceuticals INC. | $235.15 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $187.49 | 2023-2025 | Gemtesa |
| Mylan Specialty L.P. | $138.67 | 2021-2024 | Yupelri |
| Astellas Pharma US INC | $126.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $126.50 | 2021-2025 | |
| Dexcom, INC. | $117.61 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $104.93 | 2020-2023 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $79.06 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $78.93 | 2019-2022 | |
| Insulet Corporation | $76.66 | 2024-2025 | Omnipod |
| Urgo Medical North America, LLC | $72.52 | 2022 | |
| Merck Sharp & Dohme LLC | $54.23 | 2019 | |
| Pfizer INC. | $50.34 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.54 | 2021-2023 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $44.79 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $42.87 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $29.65 | 2023 | Auvelity |
| Novo Nordisk INC | $29.19 | 2019-2021 | |
| Electromed, INC. | $25.88 | 2025 | Smartvest |
| Kci USA, INC. | $24.19 | 2021 | |
| Neurocrine Biosciences, INC. | $20.90 | 2024 | Ingrezza |
| Kerecis Limited | $19.22 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Idorsia Pharmaceuticals US INC | $17.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.59 | 2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $15.98 | 2024 | Takhzyro |
| Daiichi Sankyo INC. | $15.36 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.19 | 2022 | |
| Genentech USA, INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyrel Somers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.